A therapy based on a small amino acid sequence derived from Surfactant Protein-A (SP-A) intended to reduce inflammation, mucus, and airway constriction in asthma patients.

Research involving mouse models and human airway epithelial cells to test the efficacy of SP-A derived peptides in reducing immune cell presence, mucus production, and airway hyperresponsiveness.